Eikon Therapeutics (EIKN) Registration Filing summary

Company overview and business model

• Late-stage clinical biopharmaceutical company focused on developing innovative medicines for serious unmet medical needs, with an initial focus on oncology.

• Utilizes a proprietary single molecule tracking (SMT) technology platform integrating advanced engineering, AI, and machine learning to accelerate drug discovery and development.

• Led by experienced executives with a track record in drug development and commercialization, including the development of pembrolizumab.

• Pipeline includes internally developed and in-licensed assets targeting immuno-responsive cancers, DNA repair abnormalities, and hormonally responsive cancers.

Financial performance and metrics

• Reported net losses of $243.8 million in 2024 and $244.6 million for the nine months ended September 30, 2025.

• Accumulated deficit of $840.9 million as of September 30, 2025.

• Cash, cash equivalents, and short-term investments totaled $375.9 million as of September 30, 2025.

• Research and development expenses were $204.5 million in 2024 and $185.1 million for the nine months ended September 30, 2025.

• Company expects to fund operations into the second half of 2027 with existing cash and IPO proceeds.

Use of proceeds and capital allocation

• Estimated net proceeds of $273.5 million from the IPO (or $315.4 million if underwriters' option is exercised in full) at an assumed price of $17.00 per share.

• Proceeds allocated to advance clinical development of lead candidates (EIK1001, EIK1003, EIK1004, EIK1005), fund discovery and preclinical activities, support the technology platform, and for working capital and general corporate purposes.

• Proceeds will not be sufficient to fund any product candidate through regulatory approval; additional capital will be required.